Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959835 | 0.89 | DAO (0.36) | DAOPKMLIG1HPGDRXRA | |
| SCHEMBL12785064 | 0.86 | LMNA (0.41) | HPGDLPLLIPGP4HBGLA | |
| SCHEMBL1234104 | 0.85 | NPSR1 (0.45) | HPGDGLAL3MBTL1USP30 | |
| SCHEMBL1475922 | 0.85 | F2 (0.43) | LPLLIPGP4HBUSP30 | |
| SCHEMBL30018730 | 0.83 | HPGD (0.48) | HPGDLPLLIPGP4HBKMT2A | |
| SCHEMBL2786387 | 0.82 | KDM4E (0.43) | PKMHPGDGLAKMT2AUSP30 | |
| SCHEMBL120211 | 0.79 | LPL (0.42) | LPLLIPGUSP30 | |
| SCHEMBL4150063 | 0.79 | DAO (0.41) | DAOPKMLIG1HPGDRXRA | |
| SCHEMBL13053330 | 0.79 | HDAC3 (0.48) | HPGDGLAKMT2AL3MBTL1 | |
| SCHEMBL17599482 | 0.79 | USP30 (0.46) | HPGDL3MBTL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | claimed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | claimed |
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2008077649-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1907385-A2 | COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1888573-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-02-20 | — | — | EP | disclosed |
| EP-1708697-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006125807-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
| EP-1708697-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005074642-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | DAO 4525/4885PKM 2291/4885LIG1 705/4885 |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | CMBL, EBPL, BPGM | DAO 18/4885PKM 2528/4885LIG1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.